ROCKET PHARMACEUTICALS, INC. - 10-Q Filing
Rocket Pharmaceuticals filed its 10-Q for the quarter ended March 31, 2026, providing unaudited financial results. The company reported a net loss of $29.8 million for the three months ended March 31, 2026, compared to a net loss of $24.5 million for the same period in 2025. Total research and development expenses increased to $18.2 million in Q1 2026 from $15.3 million in Q1 2025, while general and administrative expenses rose to $11.6 million from $9.2 million.
Tickers: $RCKT